Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA)   increases the expression of tumor/metastatic suppressors GRHL3 and Long ncRNA GAS5 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 21/February/2018, 6.00 am

From significance of the study to Public health relevance: 

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.

Research findings to Therapeutic opportunity: 

This study suggests, for the first time, that  a pharmaceutical mixture(DHAASA) encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA), by regulating the expression of its target genes, it may increase the expression of tumor/metastatic suppressors GRHL3 and Long ncRNA GAS5   (fig. 1).

Thereby, it may: (a) inhibit cell cycle progression; and (b) suppress migration, invasion and metastasis of cancer cells.   [easy_payment currency=”USD”]

Given the mechanism of action of DHAASA , it may be an ideal anti-metastatic agent to  (i) increase the expression of metastasis suppressor genes in tumors; (ii) inhibit the progression of metastatic tumors; and (ii) enhance the efficacy of Cancer therapy.

Taken together, this study suggests that oncologists may consider treating terminally ill metastatic cancer patients with Docosahexaenoic acid (DHA) and Aspirin (ASA) , as it may stall the progression of advanced metastatic cancers.

Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D

Amount: $5

Undisclosed mechanistic information: How a pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA)  increases the expression of  tumor/metastatic suppressors GRHL3 and Long ncRNA GAS5  

Fig1. Mechanistic insights into how a therapeutic mix encompassing  Docosahexaenoic acid (DHA) and Aspirin (ASA) functions as an anti-metastasis agent. Docosahexaenoic acid (DHA) and Aspirin (ASA)  increase the expression of tumor/metastatic suppressors GRHL3 and Long ncRNA GAS5  via up regulation of their target genes

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

References: 

Citation: Boominathan, L., Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA)   increases the expression of tumor/metastatic suppressors GRHL3 and Long ncRNA GAS5 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 21/February/2018, 6.00 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org